These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 30736159)
1. Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy. Simha V Expert Rev Endocrinol Metab; 2014 May; 9(3):205-212. PubMed ID: 30736159 [TBL] [Abstract][Full Text] [Related]
2. New advances in the treatment of generalized lipodystrophy: role of metreleptin. Rodriguez AJ; Mastronardi CA; Paz-Filho GJ Ther Clin Risk Manag; 2015; 11():1391-400. PubMed ID: 26396524 [TBL] [Abstract][Full Text] [Related]
3. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy. Akinci G; Akinci B Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498 [TBL] [Abstract][Full Text] [Related]
4. Treatment Options for Lipodystrophy in Children. Mainieri F; Tagi VM; Chiarelli F Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578 [TBL] [Abstract][Full Text] [Related]
5. Leptin replacement therapy in the management of lipodystrophy syndromes. Vigouroux C; Mosbah H; Vatier C Ann Endocrinol (Paris); 2024 Jun; 85(3):201-204. PubMed ID: 38871500 [TBL] [Abstract][Full Text] [Related]
6. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy. Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866 [TBL] [Abstract][Full Text] [Related]
7. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities. Ozgen Saydam B; Sonmez M; Simsir IY; Erturk MS; Kulaksizoglu M; Arkan T; Hekimsoy Z; Cavdar U; Akinci G; Demir T; Altay CT; Mihci E; Secil M; Akinci B Endocr Res; 2019; 44(1-2):46-54. PubMed ID: 30182761 [TBL] [Abstract][Full Text] [Related]
8. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649 [TBL] [Abstract][Full Text] [Related]
9. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. Diker-Cohen T; Cochran E; Gorden P; Brown RJ J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254 [TBL] [Abstract][Full Text] [Related]
10. Metreleptin Treatment in Three Patients with Generalized Lipodystrophy. Musso C; Major ML; Andres E; Simha V Clin Med Insights Case Rep; 2016; 9():123-127. PubMed ID: 28096701 [TBL] [Abstract][Full Text] [Related]
11. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254 [TBL] [Abstract][Full Text] [Related]
12. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of lipodystrophy: a step-by-step approach. Araújo-Vilar D; Santini F J Endocrinol Invest; 2019 Jan; 42(1):61-73. PubMed ID: 29704234 [TBL] [Abstract][Full Text] [Related]
14. Rationale for leptin-replacement therapy for severe lipodystrophy. Oral EA; Chan JL Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549 [TBL] [Abstract][Full Text] [Related]
16. Effects of Metreleptin in Pediatric Patients With Lipodystrophy. Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110 [TBL] [Abstract][Full Text] [Related]
17. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115 [TBL] [Abstract][Full Text] [Related]
18. Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report. Nagayama A; Ashida K; Moritaka K; Hidaka M; Gobaru M; Tanaka S; Hasuzawa N; Akasu S; Goto Y; Motomura S; Hara K; Tsuruta M; Wada N; Nakayama H; Tajiri Y; Nomura M J Endocr Soc; 2019 Nov; 3(11):2179-2183. PubMed ID: 31720553 [TBL] [Abstract][Full Text] [Related]
19. Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report. Pedicelli S; de Palma L; Pelosini C; Cappa M Ital J Pediatr; 2020 Oct; 46(1):158. PubMed ID: 33099310 [TBL] [Abstract][Full Text] [Related]
20. Partial lipodystrophy: Clinical presentation and treatment. Mosbah H; Vatier C; Vigouroux C Ann Endocrinol (Paris); 2024 Jun; 85(3):197-200. PubMed ID: 38871513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]